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ABSTRACT
OBJECTIVE
The objective of this selective EBM review is to determine whether or not inhaled corticosteroids
(ICS) cause an increased risk for developing or worsening a patient’s diabetes mellitus (DM).
STUDY DESIGN
Review of three English language primary studies published in 1993, 2009 and 2010.
DATA SOURCES
A nested case-control analysis, a randomized control trial and a prospective randomized, doubleblind, double-dummy, placebo-controlled, crossover investigation comparing the onset and/or
progression of diabetes mellitus in patients using ICS were found using Ovid MEDLINE,
PubMed, and Cochrane databases.
OUTCOMES MEASURED
Incidence or progression of diabetes was measured using a combination of oral glucose tolerance
test, serum insulin levels, HGbA1c levels, and fasting glucose levels.
RESULTS
Faul had 70% of patients that experienced some increase in HGbA1c levels, but none that were
statistically significant. Kiviranta had very slight increases in blood glucose when compared to
the patient’s baseline measurements. Suissa had a 34% increase in the onset or progression to
insulin use of diabetic patients.
CONCLUSIONS
While all of the studies showed an increase in the incidence or progression of diabetes in patients
taking ICS, none of the increases were significant enough to preclude diabetics from taking ICS
as needed. Careful monitoring of a patient with diabetes needing an ICS is warranted to prevent
loss of diabetes control. Additionally, a baseline HGbA1c level on a patient newly prescribed an
ICS might be beneficial.
KEYWORDS
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INTRODUCTION
According to Faul et al, the prevalence of Diabetes Mellitus (DM), chronic obstructive
pulmonary disease (COPD), and asthma are increasing.1(p14) These last two conditions, along
with others, require the use of inhaled corticosteroids (ICS). With these two facts in mind, the
likelihood that a person will be given an inhaled corticosteroid while being at risk for, or having,
DM increases at the same rate. A link between ICS use and DM incidence or progression could
have vast, yet currently unrealized, implications, as this situation, where a patient needs an ICS
and has, or is at risk for developing DM, becomes more and more common. It is likely that it will
become vital for both patients and Physician Assistants to be familiar with the effects of ICS on
blood glucose level control as it relates to DM prevention and treatment.
15% of adults have a condition, such as COPD or asthma, requiring ICS as treatment.2
25.8 million, or 8.3%, of people in the US have DM.3 DM is a very costly disease with the most
recent data from the CDC showing costs to the US of $174 billion dollars for healthcare related
to DM.3 While a firm number of visits to healthcare providers is hard to establish, $116 billion
dollars were spent on direct medical costs of the above $174 billion. Also, people with DM spent
2.3 times more on healthcare in 2007 than people without diabetes when variability between
different ages and sexes are taken into account.3 DM has a very real impact on the time patients
spend seeking healthcare and how much money they have to spend on that care.
Usually, to treat DM, there are several options used: insulin, sulfonylureas, meglitinides,
biguanides, thiazolidinediones, α-glucosidase inhibitors, or DPP-4 inhibitors. To treat asthma or
COPD, there are several inhaled corticosteroids available including flunisolide, triamcinolone
acetonide, beclomethasone dipropionate, fluticasone propionate, or budesonide. Further, other
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medications such as salmeterol, formoterol, albuterol, or levalbuterol can also be used to treat
these conditions in conjunction with ICS.2
It is known that oral corticosteroids (OCS) impair insulin action, which can lead to
hyperglycemia.4 Further, both serum glucose and glycated hemoglobin (HbA1c) are used to
distinguish between a disease state where a person has DM, is pre-diabetic, and when a person
does not have DM. These same levels are also used to monitor the disease state once a person
has a diagnosis of DM.2 Since it is known that OCS can impact DM onset and control by
affecting blood glucose levels, it stands to reason that inhaled corticosteroids could have a
similar effect on insulin action. Given the rise in people being diagnosed with a condition
requiring ICS, and that many people are facing rising risk factors for DM, due to the obesity
epidemic in the United States5, is close glucose monitoring needed to prevent incidence and
progression of DM in those using ICS?
OBJECTIVE
The objective of this selective EBM review is to determine whether or not inhaled
corticosteroids (ICS) cause an increased risk for developing or worsening a patient’s diabetes
mellitus (DM).
METHODS
The studies selected for this review focused on patients over the age of 18 who presented
using ICS or with indications for use of ICS. This class of drug also served as the interventions
for the studies and was compared to placebo and/or other medications. The outcomes measured
were progression to diabetes, change in anti-diabetic medication, or use of insulin.
Three types of studies were included in the review. One was a new-user cohort of patients
and a nested case-control analysis. Next, a randomized control trial (RCT) was used. Finally, a
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prospective randomized, double blind, double dummy, placebo-controlled, crossover
investigation was utilized for the review.
All the studies for this review were found using the Ovid MEDLINE, PubMed, and
Cochrane databases. The studies are all English language primary studies published between
1993 and 2010. The key words used in the searches were inhaled corticosteroids and diabetes.
The articles were selected based on the following inclusion criteria: first, the studies were either
RCTs or another form of primary research; second, the outcomes of the trials were found to be
patient oriented evidence that matters (POEMS); third, the articles had been published in peerreviewed journals; finally, the articles had not been used in a previously published systematic
review (SR) or meta-analysis (MA). If the study had disease-oriented evidence (DOE) only, or
had previously been used in an SR or MA, the study was excluded from this review. From these
criteria, three studies were chosen for review: The effect of an inhaled corticosteroid on glucose
control in type 2 diabetes (Faul et al)1; Effect of eight months of inhaled beclomethasone
dipropionate and budesonide on carbohydrate metabolism in adults with asthma (Kiviranta et
al)6; and Inhaled corticosteroids and the risks of diabetes onset and progression (Suissa et al)7.
The studies chosen for this review used the following statistics in reporting their data:
mean change from baseline; p-value; relative risk increase; absolute risk increase; number
needed to harm; median change from baseline; rate ratios; and confidence intervals.
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Table 1: Table of Demographics and characteristics of included studies
Age
Inclusion
Exclusion
Study
Type
# Pts
(yrs)
criteria
Criteria

Faul,
2009

Kiviranta,
1993

Suissa,
2010

Prospective
randomized,
doubleblind,
doubledummy
placebocontrolled,
crossover
investigation

14

RCT

30 (15
with
asthma,
15
control)

New-user
cohort of
patients and
a nested
case-control
analysis

388,584

52-76

Tobacco use w/i
6mo;
exacerbation of
asthma/COPD
w/i 3 mo; current
≥18 yo,
insulin use; use
DM2 by
of systemic
fasting
corticosteroids or
plasma
ICS, leukotriene
glucose
receptor
>126 mg/dl,
antagonists, or
physician dx theophylline w/i
either
1mo; inability to
asthma or
read/complete
COPD
diary card;
inability to
perform
PEF/spirometery;
inability to use
MDI with spacer

W/D

Interventions

2

Inhaled
fluticasone
propionate (440
µg twice daily)
and oral
montelukast
(10mg/day)

18-56

≥18yo,
unstable
asthma

Glucocorticoid
use

0

Inhaled
beclomethasone
dipropionate
and budesonide

66
(±15)

Dispensed
≥3
prescriptions
for
respiratory
medications
in a 1-year
period

Diagnosis of
diabetes or
dispensed a
prescription for
an anti-diabetic
drug

0

Inhaled
corticosteroids
of any type
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OUTCOMES MEASURED
The studies focused on various aspects of monitoring blood sugars and medication use as
related to the diagnosis and treatment of DM. The Faul et al study measured glucose control in
type 2 diabetic patients to avoid diabetic treatment changes using HbA1c levels.1 Kiviranta et al
measured insulin resistance possibly leading to a diagnosis of diabetes and glucose intolerance
possibly leading to a diagnosis of diabetes. This was done using the oral glucose tolerance test
(OGTT).6 Finally, Suissa et al measured incidence of diabetes and progression in severity of
diabetes. Since the study was a nested case-control analysis, it measured when patients were
advanced in their DM treatment or when anti-diabetic medication was initiated according to the
patient’s medical record.7
RESULTS
Faul et al used ten people from an outpatient setting with concomitant DM and asthma or
COPD broken into two groups. One received inhaled fluticasone propionate and oral placebo, the
other oral montelukast and inhaled placebo for six weeks at the end of which, the groups were
crossed over to the other treatment regimen for another 6 weeks. The inclusion criteria were: 18
years of age or older; type 2 DM; and a physician diagnosis of asthma or COPD on their medical
records. Patients were excluded if they used tobacco within 6 months of enrollment in the trial,
had an exacerbation of asthma/COPD within 3 months of the trial’s start, were currently using
insulin, used corticosteroids or leukotriene receptor antagonists or theophylline within 1 month
of the trial, had an inability to read or write well enough to fill out the diary, were unable to
perform pulmonary function tests, or had an inability to use a metered dose inhaler (MDI) with
spacer.1 ICS effect on glucose control was evaluated by this study as shown in Table 2. The
primary outcome measured was the difference between patients’ HbA1c levels after six weeks of
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fluticasone and when they had been on oral montelukast for six weeks. The second outcome
measured was the change from baseline of a patient after each therapy. Mean change from
baseline was +0.11 with fluticasone (SD 0.17). 20% of patients experienced an increase in
HbA1c with oral montelukast while 70% of patients experienced some increase in HbA1c with
fluticasone. The absolute risk increase was 50% with a number needed to harm of 2. While the
difference in changes of HbA1c were not statistically significant (p-value <0.025), the
researchers highly recommend close monitoring of type 2 diabetes patients needing inhaled
steroid treatment due to the large percentage of trial patients who experienced some change in
their HbA1c levels. Also prompting the recommendation was the low number needed to harm
(NNH), which, in this study, refers to the number of patients who experienced a change in their
HbA1c while taking ICS. Two patients were removed for non-compliance before randomization
of the subjects. Additionally, two patients were removed for non-compliance after the trial began,
one from each arm of the trial, so their data were simply excluded since the number of subjects
in both arms remained the same. Phone contact was made weekly with the subjects to ensure
their compliance with treatment throughout the trial.1
Table 2: Faul - Higher HgbA1c after 6 weeks of therapy1
CERa
EERb
RRIc
ARId
NNHe
p-value
20%
70%
2.5
50%
2
<0.025
a = CER (Control Event Rate) = % of patients with higher HbA1c on oral montelukast
b = EER (Experimental Event Rate) = % of patients with higher HbA1c on inhaled
fluticasone propionate
c = RRI (Relative Risk Increase), d = ARI (Absolute Risk Increase), e = NNH (Number
Needed to Harm)

Kiviranta et al studied the effects on carbohydrate metabolism in adults of both inhaled
beclomethasone dipropionate and budesonide at low doses for five months, followed by high
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doses of these drugs for three months. Fifteen individuals with unstable asthma were matched
with fifteen healthy controls for the study. Patients were included if they had currently unstable
asthma, and excluded if they had a previous history of glucocorticoid use. This study primarily
evaluated the control of asthma, but as a secondary outcome, blood glucose and insulin
sensitivity were also measured.6 This aspect of the study was measured using median change
from the baseline blood glucose and serum insulin levels of each patient. At the onset of the
study, patients were admitted to a hospital to establish a baseline for measuring their blood
glucose and serum insulin levels. Table 3 shows that the median fasting blood glucose decreased
from 4.8 mmol/L to 4.5 mmol/L at 1 month, rose to an average of 4.8 mmol/L at 5 months, and
dropped to 4.7 mmol/L at 8 months (p <0.05). Median change from baseline with fasting serum
insulin levels increased from 8mU/L to 10 mU/L with beclomethasone and decreased from 9
mU/L to 7 mU/L with budesonide at 1 month. Values for both medications leveled off around 8
mU/L for the remaining reported values at 5 and 8 months (beclomethasone – p <0.005 and
budesonide – p <0.01). The reported statistics could not be converted to dichotomous data.6 No
mention was made of how the compliance of patients was followed within the article.
Table 3: Kiviranta – Median change in blood glucose and serum insulin from baselines6
Baseline
1 Month
5 Months
8 Months
a
b
BDP
BUD
BDP
BUD
BDP
BUD
BDP
BUD
Fasting
4.8
4.8
4.5
4.5
4.7
4.9
4.7
4.7
Blood
(4.6(4.2(4.1(4.0(4.3(4.2(4.5(4.1Glucosec
5.4)
5.3)
4.9)
5.4)
5.6)
5.3)
5.0)
5.4)
Fasting
8
9
10
7
8
8
7
8
Serum
Insulind
(6-15) (6-22) (5-15) (5-20) (4-35) (5-24) (5-10) (6-25)
c,d = p-values: Fasting Blood Glucose <0.05, Fasting Serum Insulin <0.05 (BDP) and <0.01
(BUD)
Ranges in parentheses, a = BUD = Budesonide, b = BDP = Beclomethasone Dipropionate
Fasting Blood Glucose in mmol/L, Fasting Serum Insulin in mU/L
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Suissa et al formed a cohort of 388, 584 adult patients who were treated in Quebec’s
health system for respiratory disease. These patients were followed using data gleaned from the
records of patients from health insurance databases. The patients were studied until the year 2007,
or until they experienced diabetes onset/progression. The authors of the study formed a cohort of
people who had received a prescription for medication for a respiratory condition at any point
during a one-year period. Patients were excluded from selection if they had a diagnosis of
diabetes or had taken anti-diabetic medication before the beginning of the study. Once patients
had progressed to the point of diabetes, those patients who were given a prescription for an antidiabetic medication during the period of study were grouped into a sub-cohort. Patients that were
given insulin as their first anti-diabetic medication were excluded from this sub-cohort. Ten
random records matched for age to the patients of interest in the study were selected to serve as
controls for each case followed by the study.7 The study focused on whether or not ICS use
would cause DM onset or speed progression to insulin use in patients with DM. As Table 4
shows, Dichotomous data were not presented, but rather rate ratios were calculated for incidence
of diabetes (34%) and progression from oral hypoglycemic agents to insulin (34%). The
increased rate of incidence of diabetes was 34% (Rate Ratio of 1.34) with a 95% confidence
interval (CI) of 1.29-1.39. Oral hypoglycemic to insulin progression was increased at a rate of
34% (Rate Ratio of 1.34) as well, with a 95% CI of 1.17-1.53.7 Since the study was done only
using medical records, there was no way of ascertaining compliance during the time period
studied.
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Table 4: Suissa – Rate Increase in Incidence and Progression of DM with ICS use7
Rate Increase
Rate Ratio
95% CI
a
34%
1.34
1.29-1.39
Incidence
b
34%
1.34
1.17-1.53
Progression
a = Incidence refers to new incidence of DM
b = Progression refers to change from oral anti-diabetes medication to insulin
Neither the Faul el al, nor the Kiviranta et al trials had any adverse effects reported
during their studies. Suissa et al did not report on adverse effects in their nested case-control
study because the data was collected purely from medical records, making it difficult to directly
link any potential adverse effects to a single intervention.7
DISCUSSION
ICS are widely used to treat asthma and COPD.7 ICS are first-line treatments for
persistent asthma and are given to any age patient.8 While used for COPD, ICS are only useful in
limited situations when a patient has frequent exacerbations and in those cases are prescribed in
high doses.9 “ICS have been shown to have systemic effects, but their effect on glucose
metabolism in patients with type 2 diabetes has not been well defined. Although considered a
safe therapy, there are concerns about the systemic effects of ICS.”1(p14) OCS have clearly been
shown to cause an increased risk of DM, and since ICS are inhaled versions of the same class of
drugs, albeit with a different delivery, a similar set of reactions may occur with their use,
prompting the concerns about systemic effects.
The studies by Faul et al and Kiviranta were limited in size with ten and thirty subjects
respectively. Faul et al were limited in the length of time patients were treated with fluticasone in
their study. The 6-week period of treatment was shorter than may have been needed to see the
full effects of the medication, since the study measured HbA1c and red blood cells have a halflife of sixty days. This could have affected the validity of measuring the effects of the fluticasone
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treatment using HbA1c.1
CONCLUSION
Faul et al concluded that glucose control was affected by therapy with ICS, but to a
degree smaller than would usually be clinically relevant. However, since the diseases are all
increasing in prevalence, initiating a patient on ICS should prompt the clinician to consider
monitoring his or her blood glucose levels more closely than otherwise might be needed,
especially if the patient is diabetic.1 Kiviranta et al determined that an early decrease in insulin
resistance occurs, but with prolonged therapy, a slight decrease in insulin sensitivity prevails.6
Suissa et al related high doses of ICS to an increased risk of incidence of DM.7 Also, patients
with DM were more likely to progress to needing treatment with insulin.7
The evidence demonstrates that receiving inhaled corticosteroids increases a patient’s risk
for developing DM or worsening a patient’s existing DM. The risk is small according to two of
the three studies, which leads to the conclusion that while the risk exists, it should not preclude
initiation of treatment, nor prompt discontinuation of treatment. Close monitoring, however, is
strongly supported by the evidence within the studies analyzed.
Two of the three studies did not strongly differentiate between asthma and COPD, so
disease specific studies for both asthma and COPD would be excellent areas for further study.
Since the dosing and length of time a person is exposed to an ICS is different between the two
diseases, studying each disease separately may yield different conclusions from when they were
combined.8, 9 Also, the weight of patients was not factored into the calculations done by the
studies. While this is not directly linked to either COPD or asthma, it is related to an increased
risk for DM. Further, obese patients may have difficulty breathing due to their excess weight,
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which may worsen coexisting asthma or COPD. 10 It therefore bears further research to
specifically evaluate obese patients using ICS. Lastly, since the peak age of asthma onset is 3
years old, 8 it would be of benefit to study the effects of ICS use in children and adolescents. In
the studies used for this review, only adults were considered. In addition, long term use of ICS in
patients who have reached adult age and have used an ICS continuously since childhood or
adolescence would give insight into the potential long-term risks for DM onset or progression of
the most common population to have prolonged ICS exposure.2
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